Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Gilbert S. Omenn, M.D., Ph.D. as a Class II Director, with a term of office expiring in 2015 at the annual meeting of stockholders.
Help employers find you! Check out all the jobs and post your resume.
